mRNA technology targets tumors
Scientists have developed a new mRNA vaccine designed to train the immune system to attack cancer cells. In tests on mouse models of melanoma, one of the most aggressive forms of skin cancer, the vaccine produced strong results. When combined with a PD-1 inhibitor, a type of immunotherapy, even tumors that had resisted treatment became more sensitive.
The approach builds on the same mRNA technology that proved successful in COVID-19 vaccines. Instead of targeting a virus, the vaccine codes for proteins found on cancer cells, teaching the immune system to recognize and destroy them. Researchers say the platform could be adapted to target many different cancer types.
Alzheimer's treatment shows progress
In separate health news, a new Alzheimer's treatment called NeuroEPO has shown promise in clinical trials. Developed in Cuba, the drug improved cognitive function in the high-dose treatment group, while the placebo group showed expected decline. Dr. Roach, a medical columnist, highlighted the findings as offering new hope for Alzheimer's patients.
The Alzheimer's Association noted that a lack of volunteers for clinical trials remains one of the biggest obstacles to developing new treatments. They are calling for more patients to participate in research.
Early detection advances
A Mayo Clinic study found that Alzheimer's may begin causing measurable biological changes in the brain and blood during a person's late 50s, long before memory loss appears. The finding could lead to earlier diagnosis and treatment, giving patients more time to benefit from therapies.